OOIR: Observatory of International Research

Papers

(The H4-Index of Gut is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Growth rates and histopathological outcomes of small (6–9 mm) colorectal polyps based on CT colonography surveillance and endoscopic removal	1433
Defining the key intrahepatic gene networks in HCV infection driven by sex	1072
Picking up microbial clues in early-onset colorectal cancer	775
Finding a mate for MLCK: improving the potential for therapeutic targeting of gut permeability	431
Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study	306
Innumerable nodules in all parts of the small intestine	273
Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus	213
Unusual history of ‘stitch’	196
Response to McAlindon’s letter	192
Correction:P97 A patient information bundle outlining dietary advice in liver disease specific to the cost of living crisis improves patient care: ‘Looking after Your Liver for Less’	190
Unusual case of severe diarrhoea	190
Rate of suitable cases for primary EUS-guided biliary drainage in distal malignant biliary obstruction	184
Prospective, double-blind diagnostic multicentre study of confocal laser endomicroscopy for wheat sensitivity in patients with irritable bowel syndrome	174
Where are we with gastric cancer screening in Europe in 2024?	171
IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells	169
Absence of a pancreatic microbiome in intraductal papillary mucinous neoplasm	164
Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges	163
HBcrAg values may predict virological and immunological responses to pegIFN-a in NUC-suppressed HBeAg-negative chronic hepatitis B	161
Automated sizing of colorectal polyps using computer vision	160
Impact of margin thermal ablation after endoscopic mucosal resection of large (≥20 mm) non-pedunculated colonic polyps on long-term recurrence	156
A mucus production programme promotes classical pancreatic ductal adenocarcinoma	154
COVID-19 and liver disease	151
Liquid biopsy to identify Barrett’s oesophagus, dysplasia and oesophageal adenocarcinoma: theEMERALDmulticentre study	145
Methionine deficiency facilitates antitumour immunity by altering m⁶A methylation of immune checkpoint transcripts	145
Third Asia-Pacific consensus recommendations on colorectal cancer screening and postpolypectomy surveillance	145

S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos	144
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?	142
Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis	135
Gut virome-colonisingOrthohepadnavirusgenus is associated with ulcerative colitis pathogenesis and induces intestinal inflammationin vivo	134
Current therapies and new developments in NASH	134
Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study	133
Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system	133
Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?	132
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T_H17 pathogenicity and transdifferentiation	129
Impact of climate change on vulnerable populations	129
Perplexing case of abdominal pain with eosinophilia and fasciitis	129
Correction: Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	127
Intron-mediated enhancement of SPINK1 expression for pancreatitis therapy	125
Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer	124
Tumour-intrinsic alterations and stromal matrix remodelling promote Wnt-niche independence during diffuse-type gastric cancer progression	124
GI highlights from the literature	122
Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?	120
Shaggy white lesion with morphological changes in the oesophagus	120
Tiny contributors to severe obesity inside the gut	120
From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD?	113
Humoral response to SARS-CoV-2 infection among liver transplant recipients	110
Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD	109
Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19	106
Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment	105
GI highlights from the literature	105
Lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis: more doubts than answers	105
Discovery of the pancreatic basal cell: a new candidate for an adult stem cell emerges	105
Need for standardised approaches to human microbiome research using the example of colorectal neoplasia research	102
Association between appendectomy and Parkinson’s disease from the UK Biobank	99
Rare cause of obstructive jaundice	97
Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma	97
Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD	95
Unveiling 8 years of duodenoscope contamination: insights from a retrospective analysis in a large tertiary care hospital	94
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance	92
Selective decontamination of the digestive tract in critically ill children: fighting fire with fire or burning down the house?	89
Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling	89
New entity of adult ultra-short coeliac disease: the first international cohort and case–control study	89
Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression	89
British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy	88
Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model	87
Sodium⁺/taurocholate cotransporting polypeptide as target therapy for liver fibrosis	85
MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression	85
APCmosaicism, not always isolated: two first-degree relatives with apparently distinctAPCmosaicism	84
SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination	83
Endoscopic stratification of gastric intestinal metaplasia: where are we, where do we want to go and how do we get there?	83
Treatment of type 2 diabetes with MASLD: new evidence for personalised medicine	81
Environmental and healthcare trade-offs between single-use and reusable gastroscopes	81
Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity	80
Fasting-mimicking diet-enrichedBifidobacterium pseudolongumsuppresses colorectal cancer by inducing memory CD8⁺T cells	80
Rethinking routine mapping biopsies in gastric intestinal metaplasia: justification for endoscopic stratification	80

Association between inflammatory bowel disease and Alzheimer’s disease: multivariable and bidirectional Mendelian randomisation analyses	78
Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?	76
GI highlights from the literature	76